Sumitomo Pharma Am Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUMITOMO PHARMA AM, and what generic alternatives to SUMITOMO PHARMA AM drugs are available?
SUMITOMO PHARMA AM has three approved drugs.
There are thirty-six US patents protecting SUMITOMO PHARMA AM drugs.
There are four hundred and two patent family members on SUMITOMO PHARMA AM drugs in thirty-three countries and twelve supplementary protection certificates in seven countries.
Summary for Sumitomo Pharma Am
International Patents: | 402 |
US Patents: | 36 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 3 |
Drugs and US Patents for Sumitomo Pharma Am
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | 9,669,021 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | 8,846,074 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | DISCN | Yes | No | 9,669,019 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | AB | RX | Yes | No | 11,364,247 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | DISCN | Yes | No | 11,419,769 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sumitomo Pharma Am
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | 8,663,687 | ⤷ Try a Trial |
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | 9,855,221 | ⤷ Try a Trial |
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | 8,663,687 | ⤷ Try a Trial |
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | 11,077,068 | ⤷ Try a Trial |
Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | 10,888,499 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Sumitomo Pharma Am Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 104619303 | ⤷ Try a Trial |
European Patent Office | 2437896 | ⤷ Try a Trial |
European Patent Office | 2708219 | ⤷ Try a Trial |
Austria | 453424 | ⤷ Try a Trial |
Croatia | P20161619 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sumitomo Pharma Am Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0751129 | SPC/GB09/047 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTERED: UK EU/1/09/514/001 20090421; UK EU/1/09/514/002 20090421; UK EU/1/09/514/003 20090421; UK EU/1/09/514/004 20090421; UK EU/1/09/514/005 20090421; UK EU/1/09/514/006 20090421; UK EU/1/09/514/019 20090421; UK EU/1/09/514/020 20090421; UK EU/1/09/514/013 20090421; UK EU/1/09/514/014 20090421; UK EU/1/09/514/015 20090421; UK EU/1/09/514/016 20090421; UK EU/1/09/514/017 20090421; UK EU/1/09/514/018 20090421; UK EU/1/09/514/007 20090421; UK EU/1/09/514/008 20090421; UK EU/1/09/514/009 20090421; UK EU/1/09/514/010 20090421; UK EU/1/09/514/011 20090421; UK EU/1/09/514/012 20090421 |
2435025 | LUC00124 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
0751129 | 09C0040 | France | ⤷ Try a Trial | PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/514/001 DU 20090421; REGISTRATION NO/DATE AT EEC: EU/1/09/514/001 DU 20090421 |
1915346 | C01915346/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ESLICARBAZEPINACETAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67375 02.04.2020 |
2214636 | C02214636/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ESLICARBAZEPINACETAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67375 02.04.2020 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.